These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 18064910)

  • 21. [Genetic and environmental factors of Parkinson's disease].
    Broussolle E; Thobois S
    Rev Neurol (Paris); 2002; 158(122):11-23. PubMed ID: 12690311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene and protein signatures in sporadic Parkinson's disease and a novel genetic model of PD.
    Mandel SA; Fishman T; Youdim MB
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S242-7. PubMed ID: 18267243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the Engrailed mutant mice as experimental models for Parkinson's disease.
    Sgadò P; Viaggi C; Fantacci C; Corsini GU
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S103-6. PubMed ID: 18585948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unraveling the role of defective genes in Parkinson's disease.
    Dawson TM
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S248-9. PubMed ID: 18267244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The pathogenesis of Parkinson's disease: a hint from insights of familial Parkinson's disease].
    Hattori N; Kubo S
    Rinsho Shinkeigaku; 2007 Nov; 47(11):774-8. PubMed ID: 18210796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease.
    He XJ; Yamauchi H; Uetsuka K; Nakayama H
    Neurotoxicology; 2008 May; 29(3):413-20. PubMed ID: 18387672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology of Parkinson's disease.
    Bonnet AM; Houeto JL
    Biomed Pharmacother; 1999 Apr; 53(3):117-21. PubMed ID: 10349507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of motor disorders in animal models of Parkinson's disease].
    Campos-Romo A
    Rev Neurol; 2008 Feb 1-15; 46(3):167-74. PubMed ID: 18297625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
    Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
    J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene therapy in Parkinson's disease.
    Eberhardt O; Schulz JB
    Cell Tissue Res; 2004 Oct; 318(1):243-60. PubMed ID: 15322915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in Parkinson's disease-where do we stand?
    Toulouse A; Sullivan AM
    Prog Neurobiol; 2008 Aug; 85(4):376-92. PubMed ID: 18582530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the genetics of Parkinson's disease.
    Rosner S; Giladi N; Orr-Urtreger A
    Acta Pharmacol Sin; 2008 Jan; 29(1):21-34. PubMed ID: 18158863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjunctive use of the non-ionic surfactant Poloxamer 188 improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson's disease.
    Quinn M; Mukhida K; Sadi D; Hong M; Mendez I
    Eur J Neurosci; 2008 Jan; 27(1):43-52. PubMed ID: 18093176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R; Nehru B
    Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
    Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
    Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Etiology of Parkinson's disease: current concepts.
    Duvoisin RC
    Clin Neuropharmacol; 1986; 9 Suppl 1():S3-21. PubMed ID: 2423234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA knockdown as a potential therapeutic strategy in Parkinson's disease.
    Manfredsson FP; Lewin AS; Mandel RJ
    Gene Ther; 2006 Mar; 13(6):517-24. PubMed ID: 16267570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo gene delivery for development of mammalian models for Parkinson's disease.
    Ulusoy A; Bjorklund T; Hermening S; Kirik D
    Exp Neurol; 2008 Jan; 209(1):89-100. PubMed ID: 18028909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.